, PPV

, Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group, Br J Haematol, vol.121, pp.749-57, 2003.

A. Dispenzieri, R. A. Kyle, J. A. Katzmann, T. M. Therneau, D. Larson et al., Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma, Blood, vol.111, pp.785-794, 2008.

A. Dispenzieri, R. Kyle, G. Merlini, J. S. Miguel, H. Ludwig et al., International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, Leukemia, vol.23, pp.215-239, 2009.

J. T. Larsen, S. K. Kumar, A. Dispenzieri, R. A. Kyle, and J. A. Katzmann, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma, Leukemia, vol.27, pp.941-947, 2013.

A. Lakshman, S. V. Rajkumar, F. K. Buadi, M. Binder, M. A. Gertz et al., Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria, Blood Cancer J, vol.8, p.59, 2018.

L. López-corral, N. C. Gutiérrez, M. B. Vidriales, M. V. Mateos, A. Rasillo et al., The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, pp.1692-700, 2011.

R. A. Kyle, E. D. Remstein, T. M. Therneau, A. Dispenzieri, P. J. Kurtin et al., Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, N Engl J Med, vol.356, pp.2582-90, 2007.

C. Cesana, C. Klersy, L. Barbarano, A. M. Nosari, M. Crugnola et al., Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, pp.1625-1659, 2002.

P. Ravi, S. Kumar, J. T. Larsen, W. Gonsalves, F. Buadi et al., Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma, Blood Cancer J, vol.6, p.454, 2016.

C. Fernández-de-larrea, I. Isola, A. Pereira, M. T. Cibeira, L. Magnano et al., Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression, Leukemia, vol.32, pp.1427-1461, 2018.

S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo, J. Blade, G. Merlini et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-586, 2014.

V. Wu, E. Moshier, S. Leng, B. Barlogie, H. J. Cho et al., Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling, Blood Adv, vol.2, pp.1470-1479, 2018.

A. R. Bradwell, H. D. Carr-smith, G. P. Mead, L. X. Tang, P. J. Showell et al., Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine, Clin Chem, vol.47, pp.673-80, 2001.

H. Velthuis, I. Knop, P. Stam, M. Van-den-broek, H. K. Bos et al., N Latex FLC -new monoclonal high-performance assays for the determination of free light chain kappa and lambda, Clin Chem Lab Med, vol.49, pp.1323-1355, 2011.

J. P. Campbell, J. L. Heaney, M. Shemar, D. Baldwin, A. E. Griffin et al., Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum ? and ? immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool, Clin Chem Lab Med, vol.55, pp.424-458, 2017.

J. F. Jacobs, C. M. De-kat-angelino, H. M. Brouwers, S. A. Croockewit, I. Joosten et al., Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods, Clin Chem Lab Med, vol.56, pp.312-334, 2018.

R. M. Hoedemakers, J. F. Pruijt, S. Hol, E. Teunissen, H. Martens et al., Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis, Clin Chem Lab Med, vol.50, pp.489-95, 2012.

D. Noto, G. Cimpoies, E. Dossi, A. Paolini, L. Radeghieri et al., Polyclonal versus monoclonal immunoglobulin-free light chains quantification, Ann Clin Biochem, vol.52, pp.327-363, 2015.

C. A. Hutchison, P. Cockwell, and M. Cook, Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy, BMC Clin Pathol, vol.12, p.12, 2012.

H. D. Carr-smith, E. L. Jenner, J. A. Evans, and S. J. Harding, Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents, Clin Chem Lab Med, vol.54, pp.997-1003, 2016.

C. Moreau, B. Autier, T. Cavey, E. Rouger, J. Norwood et al., Evaluation of the impact of renal failure on correlation and concordance between 2 free light chain assays, Clin Lymphoma Myeloma Leuk, vol.16, pp.693-704, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01427008

R. Sabatino, A. Perrone, M. Cuomo, S. Liotti, V. Barchiesi et al., Analytical criticalities associated to different immunological methods for serum free light chain detection in plasma cell dyscrasias: a description of particular clinical cases, Int J Mol Sci, vol.18, p.804, 2017.

A. Messiaen, D. Sloovere, M. M. , C. Vercammen, M. Van-hoovels et al., Performance evaluation of serum free light chain analysis: nephelometry vs. turbidimetry, monoclonal vs. polyclonal reagents, Am J Clin Pathol, vol.147, pp.611-633, 2017.

S. V. Rajkumar, D. Larson, and R. A. Kyle, Diagnosis of smoldering multiple myeloma, N Engl J Med, vol.365, pp.474-479, 2011.

S. Atrash, M. Robinson, D. Slaughter, A. Aneralla, T. Brown et al., Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma, Blood Cancer J, vol.8, p.107, 2018.

M. A. Aljama, M. H. Sidiqi, A. Lakshman, A. Dispenzieri, D. Jevremovic et al., Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma, Blood Adv, vol.2, pp.3149-54, 2018.

E. Kastritis, E. Terpos, L. Moulopoulos, M. Spyropoulou-vlachou, N. Kanellias et al., Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease, Leukemia, vol.27, pp.947-53, 2013.

R. Sørrig, T. W. Klausen, M. Salomo, A. J. Vangsted, B. Gregersen et al., Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study, Eur J Haematol, vol.97, pp.303-312, 2016.

M. Mateos and V. González-calle, Smoldering Multiple Myeloma: Who and When to Treat, Clin Lymphoma Myeloma Leuk, vol.17, pp.716-738, 2017.

S. K. Kumar, Timing of treatment of smoldering myeloma: delay until progression, Blood Adv, vol.2, pp.3050-3053, 2018.

M. Mateos and V. González-calle, Timing of treatment of smoldering myeloma: early treatment, Blood Adv, vol.2, pp.3045-3054, 2018.